Rhythm Highlights Positive Phase 3 Data in Hypothalamic Obesity
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rhythm Pharmaceuticals ( (RYTM) ) just unveiled an update.
On March 1, 2026, Rhythm Pharmaceuticals reported additional 52-week data from its global Phase 3 TRANSCEND trial of setmelanotide in acquired hypothalamic obesity, expanding the pivotal dataset to 142 patients, including 12 from Japan and 10 supplemental patients. The results showed an 18.8% placebo-adjusted BMI reduction, with patients on setmelanotide achieving a mean 16.4% BMI decrease versus a 2.4% BMI increase on placebo, and in patients aged 12 and older the drug also delivered greater reductions in hunger scores than placebo.
These findings strengthen the clinical profile of setmelanotide as Rhythm seeks an expanded indication, with a supplemental New Drug Application under U.S. FDA review and a PDUFA goal date of March 20, 2026, and parallel regulatory reviews ongoing in Europe and planned in Japan. If approvals follow, the data could position Rhythm as the first company with an approved therapy specifically for acquired hypothalamic obesity, potentially broadening its commercial footprint across an estimated 25,000 to 28,000 patients in the U.S., Europe and Japan and reinforcing its standing in the rare obesity segment.
The most recent analyst rating on (RYTM) stock is a Hold with a $104.00 price target. To see the full list of analyst forecasts on Rhythm Pharmaceuticals stock, see the RYTM Stock Forecast page.
Spark’s Take on RYTM Stock
According to Spark, TipRanks’ AI Analyst, RYTM is a Neutral.
The score is driven primarily by strong revenue growth and high gross margins alongside a low-leverage balance sheet, but is held back by continued heavy cash burn and losses. Technicals are weak with the stock trading below key moving averages, while valuation is constrained by negative earnings. Earnings-call updates provide some support via strong growth, upcoming catalysts, and a multi-year cash runway, but higher 2026 spending and clinical/regulatory execution risks remain material.
To see Spark’s full report on RYTM stock, click here.
More about Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, with headquarters in Boston, MA. Its lead asset, IMCIVREE (setmelanotide), an MC4R agonist for hyperphagia and severe obesity, is already approved in the U.S., European Union and U.K. for certain syndromic and monogenic obesity indications in adults and children.
The company is also advancing broader clinical programs for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical small-molecule portfolio targeting congenital hyperinsulinism.
Rhythm’s market focus centers on rare, genetically driven or hypothalamic-mediated forms of severe obesity, where it seeks to build a leadership position in precision neuroendocrine therapies across the U.S., Europe, Japan and additional global markets.
Average Trading Volume: 778,316
Technical Sentiment Signal: Buy
Current Market Cap: $6.33B
See more insights into RYTM stock on TipRanks’ Stock Analysis page.
